Information on valuation, funding, cap tables, investors, and executives for Intellia. Use the PitchBook Platform to explore the full profile.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA.

Intellia (Information Services) has 6 total employees. What industry is Intellia (Information Services) in? Intellia (Information Services)’s primary industry is Information Services (B2C).

Voyager Therapeutics, Intellia Therapeutics, LyGenesis, FUJIFILM Irvine Scientific, and Immusoft are some of the 45 competitors of Egenesis.

ImmunOs Therapeutics, Palleon Pharmaceuticals, and Intellia Therapeutics are competitors of Immetas.

Myriad Genetics, ERS Genomics, Ambry Genetics, Intellia Therapeutics, and Anaveon are some of the 44 competitors of CeGaT.

Casma Therapeutics, Abeona Therapeutics, Intellia Therapeutics, and Beam Therapeutics are competitors of Neuron23.